A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
A phase 3 trial of Sintilimab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting.
Overview
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer is a phase 3 interventional study registered as NCT05890742 by Innovent Biologics (Suzhou) Co. Ltd., with 453 participants enrolled, started 2023-05-25 and due to reach its primary completion in 2028-04-15. Interventions recorded: Sintilimab, IBI310&Sintilimab and Radical surgery.
Similar pages
not linked directly; found by shared links- TrialAssessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Shares Sintilimab and the tag pipeline.
- TrialXian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of Gixam's Performance in a FIT Negative Population
Shares Colorectal cancer and the tag pipeline.
- TrialIsunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Shares Colorectal cancer and the tag pipeline.
- TrialTo Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.